mitomycin has been researched along with Fuchs' Endothelial Dystrophy in 1 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Fuchs' Endothelial Dystrophy: Disorder caused by loss of endothelium of the central cornea. It is characterized by hyaline endothelial outgrowths on Descemet's membrane, epithelial blisters, reduced vision, and pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the anterior corneal surface regularity and light scattering before and after Descemet membrane endothelial keratoplasty (DMEK) with epithelial debridement and application of mitomycin C in Fuchs dystrophy-affected eyes with preoperative subepithelial fibrosis or anterior basement membrane dystrophy." | 7.80 | Descemet membrane endothelial keratoplasty combined with epithelial debridement and mitomycin-C application for fuchs dystrophy with preoperative subepithelial fibrosis or anterior basement membrane dystrophy. ( Chaurasia, S; McKee, Y; Price, FW; Price, MO, 2014) |
| "The aim of this study was to evaluate the anterior corneal surface regularity and light scattering before and after Descemet membrane endothelial keratoplasty (DMEK) with epithelial debridement and application of mitomycin C in Fuchs dystrophy-affected eyes with preoperative subepithelial fibrosis or anterior basement membrane dystrophy." | 3.80 | Descemet membrane endothelial keratoplasty combined with epithelial debridement and mitomycin-C application for fuchs dystrophy with preoperative subepithelial fibrosis or anterior basement membrane dystrophy. ( Chaurasia, S; McKee, Y; Price, FW; Price, MO, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaurasia, S | 1 |
| Price, MO | 1 |
| McKee, Y | 1 |
| Price, FW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-enrollment, Prospective Study of Endothelial Keratoplasty Outcomes[NCT00800111] | 2,593 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for mitomycin and Fuchs' Endothelial Dystrophy
| Article | Year |
|---|---|
Descemet membrane endothelial keratoplasty combined with epithelial debridement and mitomycin-C application for fuchs dystrophy with preoperative subepithelial fibrosis or anterior basement membrane dystrophy.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Basement Membrane; Corneal Endothelial Cell Loss; | 2014 |